Larimar Therapeutics (LRMR) Insider Trading & Ownership $1.78 -0.01 (-0.28%) As of 11:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Larimar Therapeutics (NASDAQ:LRMR) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.50%Number OfInsiders Buying(Last 3 Years)5Amount OfInsider Buying(Last 3 Years)$39.65 MNumber OfInsiders Selling(Last 3 Years)0 Get LRMR Insider Trade Alerts Want to know when executives and insiders are buying or selling Larimar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address LRMR Insider Buying and Selling by Quarter Larimar Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/16/2024James E FlynnDirectorBuy4,290,617$8.74$37,499,992.58 2/14/2024Frank E ThomasDirectorBuy2,000$11.00$22,000.00 5/17/2023Joseph TruittDirectorBuy2,750$3.73$10,257.50 5/17/2023Michael CelanoCFOBuy5,000$3.73$18,650.00 9/16/2022Michael CelanoCFOBuy31,746$3.15$99,999.90 9/16/2022Thomas Edward HamiltonDirectorBuy317,460$3.15$999,999.00 9/16/2022Thomas Edward HamiltonDirectorBuy317,460$3.15$999,999.00 (Data available from 1/1/2013 forward) LRMR Insider Trading Activity - Frequently Asked Questions Who is on Larimar Therapeutics's Insider Roster? The list of insiders at Larimar Therapeutics includes Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano, and Thomas Edward Hamilton. Learn more on insiders at LRMR. What percentage of Larimar Therapeutics stock is owned by insiders? 4.50% of Larimar Therapeutics stock is owned by insiders. Learn more on LRMR's insider holdings. Which Larimar Therapeutics insiders have been buying company stock? The following insiders have purchased LRMR shares in the last 24 months: Frank E Thomas ($22,000.00), James E Flynn ($37,499,992.58), Joseph Truitt ($10,257.50), and Michael Celano ($18,650.00). How much insider buying is happening at Larimar Therapeutics? Insiders have purchased a total of 4,300,367 LRMR shares in the last 24 months for a total of $37,550,900.08 bought. Larimar Therapeutics Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Compensation: $865kMr. Michael Celano CPA (Age 65)Secretary & CFO Compensation: $577.58kDr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Compensation: $593.02kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, D.O., Chief Medical Officer Mr. Francis Michael Conway CPAVP & Controller More Insider Trading Tools from MarketBeat Related Companies ORGO Insider Transactions ABCL Insider Transactions KALV Insider Transactions COGT Insider Transactions BCYC Insider Transactions ANAB Insider Transactions AKBA Insider Transactions CDXC Insider Transactions KROS Insider Transactions CRMD Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market CapMcDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish Outlook This page (NASDAQ:LRMR) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
